Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK-Adjusted vs Fixed-Dose Busulfan with Fludarabine in HSCT for AML/MDS
NCT00469144Phase 3Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2005
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of busulfan in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2005; status: completed.
02
Drugs
busulfan
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00469144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00469144.